136 results
Page 2 of 7
8-K
EX-99.2
clrns9l
10 Oct 23
Regulation FD Disclosure
8:04am
8-K
tzd68jsrv360hhmcjx
26 Jun 23
Submission of Matters to a Vote of Security Holders
4:02pm
8-K
EX-99.2
v9c0v10u7p 33
5 Jun 23
Results of Operations and Financial Condition
8:05am
8-K
EX-1.1
9obp9jmdgesql pncew9
17 May 23
Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock
5:01pm
8-K
EX-5.1
2w109m wj
17 May 23
Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock
5:01pm
424B5
dpx1npvn0k 3dfdgw0
17 May 23
Prospectus supplement for primary offering
4:45pm
8-K
EX-1.1
mruja0w vzzexg
16 Sep 22
Entry into a Material Definitive Agreement
4:02pm
8-K
EX-5.1
v0lb kjzcbbl68ym
16 Sep 22
Entry into a Material Definitive Agreement
4:02pm
424B5
glu 40grbbpu9xnw
15 Sep 22
Prospectus supplement for primary offering
5:16pm
424B5
4air7jw
13 Sep 22
Prospectus supplement for primary offering
5:11pm
8-K
EX-99.2
c8qn20
13 Sep 22
Regulation FD Disclosure
9:07am
8-K
EX-5.1
s1n0kiwf
16 Jun 22
Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million
7:14am